<?xml version="1.0" encoding="UTF-8"?>

<ActivityDefinition xmlns="http://hl7.org/fhir">
  <id value="MoxifloxacinRequest"/>
  <text>
    <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: ActivityDefinition MoxifloxacinRequest</b></p><a name="MoxifloxacinRequest"> </a><a name="hcMoxifloxacinRequest"> </a><a name="MoxifloxacinRequest-en-US"> </a><p><b>url</b>: <a href="ActivityDefinition-MoxifloxacinRequest.html">ActivityDefinition Moxifloxacin Request</a></p><p><b>identifier</b>: Anthrax_Post_Exposure_Prophylaxis_FHIRv102_CQL_v110/MoxifloxacinRequest</p><p><b>version</b>: 1.1.0</p><p><b>name</b>: Anthrax_Post_Exposure_Prophylaxis_Adults_Moxifloxacin_Request</p><p><b>title</b>: Moxifloxacin Request</p><p><b>status</b>: Draft</p><p><b>experimental</b>: true</p><p><b>date</b>: 2024-11-18 16:30:23+0000</p><p><b>publisher</b>: HL7 International - Clinical Decision Support WG</p><p><b>contact</b>: HL7 International - Clinical Decision Support WG: <a href="http://www.hl7.org/Special/committees/dss/index.cfm">http://www.hl7.org/Special/committees/dss/index.cfm</a></p><p><b>description</b>: </p><div><p>In 2009, the US Advisory Committee on Immunization Practices recommended in addition to antimicrobial therapy, a 3-dose series of Anthrax Vaccine Adsorbed (AVA) BioThrax (Emergent BioSolutions Inc., Rockville, MD, USA) for long-term protection after exposure to anthrax  in individuals without any previous vaccine. After exposure to aerosolized B. anthracis spores, antimicrobial therapy should be initiated as soon as possible. Ideally, the first dose of vaccine should be administered within 10 days. ACIP recommends a post exposure regimen of 60 days of appropriate antimicrobial prophylaxis (covered previously) combined with 3 subcutaneous doses of AVA (administered at 0, 2, and 4 weeks post exposure) as the most effective protection against inhalation anthrax for previously unvaccinated persons aged ≥18 years who have been exposed to aerosolized B. anthracis spores. In general, the peak serologic response to anthrax vaccine occurs 10–14 days after the third dose. (Wright, J.G et al., Morbidity and Mortality Weekly Report, July 23, 2010 / 59(RR06); 1-30). Additionally, the Advisory Committee on Immunization Practices subsequently reviewed all safety data available as of March 2008, including the final results of a retrospective study, and concluded that AVA is safe to administer to anthrax-exposed women during pregnancy. In the setting of an anthrax event that poses a high risk for exposure to aerosolized B. anthracis spores, pregnancy is neither a precaution nor a contraindication to vaccination. Pregnant women at risk for inhalation anthrax should receive AVA and antimicrobial drug therapy regardless of pregnancy trimester (Meanye-Delman D et al., Emerg Infect Dis, 20(2), 2014).</p>
</div><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="http://terminology.hl7.org/6.0.2/CodeSystem-usage-context-type.html#usage-context-type-age">UsageContextType age</a>: Age Range</td><td>18-?</td></tr><tr><td style="display: none">*</td><td><a href="http://terminology.hl7.org/6.0.2/CodeSystem-usage-context-type.html#usage-context-type-venue">UsageContextType venue</a>: Clinical Venue</td><td><span title="Codes:{http://snomed.info/sct 440655000}">Outpatient environment</span></td></tr><tr><td style="display: none">*</td><td><a href="http://terminology.hl7.org/6.0.2/CodeSystem-usage-context-type.html#usage-context-type-focus">UsageContextType focus</a>: Clinical Focus</td><td><span title="Codes:{http://hl7.org/fhir/sid/icd-10-cm Z20.810}">Contact with and (suspected) exposure to anthrax</span></td></tr><tr><td style="display: none">*</td><td><a href="http://terminology.hl7.org/6.0.2/CodeSystem-usage-context-type.html#usage-context-type-focus">UsageContextType focus</a>: Clinical Focus</td><td><span title="Codes:{http://snomed.info/sct 170475009}">Exposure to Bacillus anthracis (event)</span></td></tr><tr><td style="display: none">*</td><td><a href="http://terminology.hl7.org/6.0.2/CodeSystem-usage-context-type.html#usage-context-type-focus">UsageContextType focus</a>: Clinical Focus</td><td><span title="Codes:{http://snomed.info/sct 84387000}">Asymptomatic (finding)</span></td></tr></table><p><b>jurisdiction</b>: <span title="Codes:{http://unstats.un.org/unsd/methods/m49/m49.htm 001}">World</span></p><p><b>purpose</b>: </p><div><p>Provides clinicians with information for quickly assessing individuals exposed to anthrax unrelated to occupational exposure, for example in bioterrorism events, and provides the recommended post-exposure prophylaxis (PEP) regimen for asymptomatic patients. Includes immediate treatment with antimicrobials and vaccine and follow-up administration of subsequent vaccines to complete the recommended 3-dose vaccination series.</p>
</div><p><b>usage</b>: Intended for use by clinicians caring for individuals ≥18 years of age in an outpatient setting.</p><p><b>approvalDate</b>: 2019-06-07</p><p><b>lastReviewDate</b>: 2019-06-07</p><p><b>effectivePeriod</b>: 2019-06-07 --&gt; (ongoing)</p><p><b>topic</b>: <span title="Codes:">Anthrax</span>, <span title="Codes:">Emergency Medicine</span>, <span title="Codes:">Post-Exposure Prophylaxis</span></p><p><b>author</b>: Alliance to Modernize Healthcare FFRDC: </p><p><b>endorser</b>: Centers for Disease Control and Prevention: </p><p><b>kind</b>: MedicationRequest</p><p><b>product</b>: <span title="Codes:{http://www.nlm.nih.gov/research/umls/rxnorm 311787}">moxifloxacin HCl 400 MG Oral Tablet</span></p><p><b>quantity</b>: 60(unit ORTAB from http://terminology.hl7.org/CodeSystem/v3-orderableDrugForm)<span style="background: LightGoldenRodYellow"> (Details: Orderable Drug Form  codeORTAB = 'Oral Tablet')</span></p><h3>Dosages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Text</b></td><td><b>AdditionalInstruction</b></td><td><b>Timing</b></td><td><b>Route</b></td><td><b>Method</b></td></tr><tr><td style="display: none">*</td><td>One every day for 60 days</td><td><span title="Codes:">none</span></td><td>Once per 1 days</td><td><span title="Codes:{http://snomed.info/sct 26643006}">Oral Route</span></td><td><span title="Codes:{http://snomed.info/sct 421521009}">Swallow - dosing instruction imperative (qualifier value)</span></td></tr></table></div>
  </text>
  <url value="http://hl7.org/fhir/uv/cpg/anthrax/ActivityDefinition/MoxifloxacinRequest"/>
  <identifier>
    <value value="Anthrax_Post_Exposure_Prophylaxis_FHIRv102_CQL_v110/MoxifloxacinRequest"/>
  </identifier>
  <version value="1.1.0"/>
  <name value="Anthrax_Post_Exposure_Prophylaxis_Adults_Moxifloxacin_Request"/>
  <title value="Moxifloxacin Request"/>
  <status value="draft"/>
  <experimental value="true"/>
  <date value="2024-11-18T16:30:23+00:00"/>
  <publisher value="HL7 International - Clinical Decision Support WG"/>
  <contact>
    <name value="HL7 International - Clinical Decision Support WG"/>
    <telecom>
      <system value="url"/>
      <value value="http://www.hl7.org/Special/committees/dss/index.cfm"/>
    </telecom>
  </contact>
  <description value="In 2009, the US Advisory Committee on Immunization Practices recommended in addition to antimicrobial therapy, a 3-dose series of Anthrax Vaccine Adsorbed (AVA) BioThrax (Emergent BioSolutions Inc., Rockville, MD, USA) for long-term protection after exposure to anthrax  in individuals without any previous vaccine. After exposure to aerosolized B. anthracis spores, antimicrobial therapy should be initiated as soon as possible. Ideally, the first dose of vaccine should be administered within 10 days. ACIP recommends a post exposure regimen of 60 days of appropriate antimicrobial prophylaxis (covered previously) combined with 3 subcutaneous doses of AVA (administered at 0, 2, and 4 weeks post exposure) as the most effective protection against inhalation anthrax for previously unvaccinated persons aged ≥18 years who have been exposed to aerosolized B. anthracis spores. In general, the peak serologic response to anthrax vaccine occurs 10–14 days after the third dose. (Wright, J.G et al., Morbidity and Mortality Weekly Report, July 23, 2010 / 59(RR06); 1-30). Additionally, the Advisory Committee on Immunization Practices subsequently reviewed all safety data available as of March 2008, including the final results of a retrospective study, and concluded that AVA is safe to administer to anthrax-exposed women during pregnancy. In the setting of an anthrax event that poses a high risk for exposure to aerosolized B. anthracis spores, pregnancy is neither a precaution nor a contraindication to vaccination. Pregnant women at risk for inhalation anthrax should receive AVA and antimicrobial drug therapy regardless of pregnancy trimester (Meanye-Delman D et al., Emerg Infect Dis, 20(2), 2014)."/>
  <useContext>
    <code>
      <system value="http://terminology.hl7.org/CodeSystem/usage-context-type"/>
      <code value="age"/>
      <display value="Age Range"/>
    </code>
    <valueRange>
      <low>
        <value value="18"/>
      </low>
    </valueRange>
  </useContext>
  <useContext>
    <code>
      <system value="http://terminology.hl7.org/CodeSystem/usage-context-type"/>
      <code value="venue"/>
      <display value="Clinical Venue"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="440655000"/>
        <display value="Outpatient environment"/>
      </coding>
    </valueCodeableConcept>
  </useContext>
  <useContext>
    <code>
      <system value="http://terminology.hl7.org/CodeSystem/usage-context-type"/>
      <code value="focus"/>
      <display value="Clinical Focus"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="http://hl7.org/fhir/sid/icd-10-cm"/>
        <code value="Z20.810"/>
        <display value="Contact with and (suspected) exposure to anthrax"/>
      </coding>
    </valueCodeableConcept>
  </useContext>
  <useContext>
    <code>
      <system value="http://terminology.hl7.org/CodeSystem/usage-context-type"/>
      <code value="focus"/>
      <display value="Clinical Focus"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="170475009"/>
        <display value="Exposure to Bacillus anthracis (event)"/>
      </coding>
    </valueCodeableConcept>
  </useContext>
  <useContext>
    <code>
      <system value="http://terminology.hl7.org/CodeSystem/usage-context-type"/>
      <code value="focus"/>
      <display value="Clinical Focus"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="84387000"/>
        <display value="Asymptomatic (finding)"/>
      </coding>
    </valueCodeableConcept>
  </useContext>
  <jurisdiction>
    <coding>
      <system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/>
      <code value="001"/>
      <display value="World"/>
    </coding>
  </jurisdiction>
  <purpose value="Provides clinicians with information for quickly assessing individuals exposed to anthrax unrelated to occupational exposure, for example in bioterrorism events, and provides the recommended post-exposure prophylaxis (PEP) regimen for asymptomatic patients. Includes immediate treatment with antimicrobials and vaccine and follow-up administration of subsequent vaccines to complete the recommended 3-dose vaccination series."/>
  <usage value="Intended for use by clinicians caring for individuals ≥18 years of age in an outpatient setting."/>
  <approvalDate value="2019-06-07"/>
  <lastReviewDate value="2019-06-07"/>
  <effectivePeriod>
    <start value="2019-06-07"/>
  </effectivePeriod>
  <topic>
    <text value="Anthrax"/>
  </topic>
  <topic>
    <text value="Emergency Medicine"/>
  </topic>
  <topic>
    <text value="Post-Exposure Prophylaxis"/>
  </topic>
  <author>
    <name value="Alliance to Modernize Healthcare FFRDC"/>
  </author>
  <endorser>
    <name value="Centers for Disease Control and Prevention"/>
  </endorser>
  <kind value="MedicationRequest"/>
  <productCodeableConcept>
    <coding>
      <system value="http://www.nlm.nih.gov/research/umls/rxnorm"/>
      <code value="311787"/>
      <display value="moxifloxacin HCl 400 MG Oral Tablet"/>
    </coding>
    <text value="moxifloxacin HCl 400 MG Oral Tablet"/>
  </productCodeableConcept>
  <quantity>
    <value value="60"/>
    <system value="http://terminology.hl7.org/CodeSystem/v3-orderableDrugForm"/>
    <code value="ORTAB"/>
  </quantity>
  <dosage>
    <text value="One every day for 60 days"/>
    <additionalInstruction>
      <text value="none"/>
    </additionalInstruction>
    <timing>
      <repeat>
        <frequency value="1"/>
        <period value="1"/>
        <periodUnit value="d"/>
      </repeat>
    </timing>
    <route>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="26643006"/>
        <display value="Oral Route"/>
      </coding>
    </route>
    <method>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="421521009"/>
        <display value="Swallow - dosing instruction imperative (qualifier value)"/>
      </coding>
    </method>
  </dosage>
</ActivityDefinition>